Ketoconazole as Inhibitor of the Enzyme CYP17 in Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary

Inclusion Criteria: * Patients obtained their written informed consent. * Women ≥18 years old. * ECOG ≤ 1. * Histologically confirmed carcinoma of granulosa cell in ovary. * Availability of sufficient biopsy material to confirm the diagnosis by a centralized pathologist and determination of the FOXL2 402C mutation → G (C134W). * Metastatic or unresectable disease. * Imaging measurable disease. * Life expectancy ≥ 12 weeks. * Patients with adequate hepatic function, defined by: * Serum values of AST and ALT ≤ 3 x UNL (except in the presence of metastases then allowed values ≤ 5 x UNL) * Total bilirubin ≤ 1.5 x UNL * Patients with adequate bone marrow function, defined by: * Absolute neutrophil count ≥ 1.5 x 10\*9 / L * Platelets ≥ 100 x 10\*9 / L * Hb \> 9 g / dL * Patients with adequate renal function: serum creatinine ≤ 1.5 x UNL. * Absence of any impediment to comply with the study protocol. * Women of childbearing potential, sexually active, not under hysterectomy or bilateral adnexectomy, should follow the following guidelines on contraception: * Negative serum or urine pregnancy test within 72 hours before the start of treatment. * Use of a medically accepted contraceptive method during: the 2 months prior to study treatment, during the study and 3 months after the last dose of study treatment. Exclusion Criteria: * Patients with another primary tumor 2 years before starting the study drug, with the exception of cervical carcinoma in situ or adequately treated or remo…